Huadong Pharmaceutical: Liraglutide injections for diabetes indications and those for obesity or overweight are all expected to be approved for marketing this year
Breakings · 02/22 09:14
华东医药在互动平台表示，公司用于治疗铂耐药卵巢癌的全球首创ADC药物 HDM2002（IMGN853）、用于治疗成年中重度斑块状银屑病的原研药乌司奴单抗（Stelara，喜达诺）的生物类似药HDM3001（QX001S）有望于今年在国内递交BLA；与 MediBeacon肾小球滤过率动态监测系统配合使用的荧光示踪剂MB-102注射液有望于今年递交上市申请；公司迈华替尼片目前正在进行III期临床试验，预计有望于今年递交上市申请；利拉鲁肽注射液糖尿病适应症及肥胖或超重适应症均有望在今年获批上市。
Risk disclosure: The above content only represents the opinion of the authors or guests, and does not represent any positions of Futu or constitute any investment advice on the part of Futu. Before making any investment decision, investors should consider the risk factors related to investment products based on their own circumstances and consult professional investment advisers where necessary. Futu makes every effort to verify the authenticity, accuracy, and originality of the above content, but does not make any guarantees or promises.